CN101590168A - A kind of Chinese medicine composition that is used for the treatment of gout and preparation method thereof - Google Patents
A kind of Chinese medicine composition that is used for the treatment of gout and preparation method thereof Download PDFInfo
- Publication number
- CN101590168A CN101590168A CNA2008101132159A CN200810113215A CN101590168A CN 101590168 A CN101590168 A CN 101590168A CN A2008101132159 A CNA2008101132159 A CN A2008101132159A CN 200810113215 A CN200810113215 A CN 200810113215A CN 101590168 A CN101590168 A CN 101590168A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- preparation
- medicine composition
- radix
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 238000001035 drying Methods 0.000 claims abstract description 29
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims description 37
- 238000002156 mixing Methods 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 238000002481 ethanol extraction Methods 0.000 claims description 11
- 239000012567 medical material Substances 0.000 claims description 11
- 239000006187 pill Substances 0.000 claims description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 5
- 230000003179 granulation Effects 0.000 claims description 5
- 235000012907 honey Nutrition 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 3
- 241000241550 Cyathula Species 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 239000002934 diuretic Substances 0.000 abstract description 5
- 230000001882 diuretic effect Effects 0.000 abstract description 5
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 17
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 210000000544 articulatio talocruralis Anatomy 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 11
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical group N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 7
- 206010018634 Gouty Arthritis Diseases 0.000 description 6
- 230000036285 pathological change Effects 0.000 description 6
- 231100000915 pathological change Toxicity 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 239000002574 poison Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000004144 purine metabolism Effects 0.000 description 3
- 230000001047 pyretic effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 208000003899 Foreign-Body Granuloma Diseases 0.000 description 2
- 208000005422 Foreign-Body reaction Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010030302 Oliguria Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000002309 gasification Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000002407 reforming Methods 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NTDFJPCHHGBHCO-UHFFFAOYSA-N 7,9-dihydro-3H-purine-2,6,8-trione Chemical compound OC1=NC(O)=C2NC(O)=NC2=N1.N1C(=O)NC(=O)C2=C1NC(=O)N2 NTDFJPCHHGBHCO-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000008763 Mercury poisoning Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020825 overweight Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 150000007968 uric acids Chemical class 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of Chinese medicine composition for the treatment of gout and preparation method thereof.This Chinese medicine composition is to be prepared from according to a certain weight ratio by Rhizoma Smilacis Glabrae, Radix Cyathulae, Cortex Phellodendri, Radix Et Rhizoma Rhei, Rhizoma Alismatis, Herba Plantaginis.It can be prepared to any common drug dosage form.Chinese medicine composition of the present invention has the effect of heat clearing and damp drying, detoxifcation, diuretic, easing joint movement, is used for the treatment of gout.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition that is used for the treatment of gout and preparation method thereof, belong to the field of Chinese medicines.
Background technology
Gout is uric acid crystal and tissue injury's property disease of causing in purine metabolism obstacle and the blood in the body.Various disease conditions such as clinical characters is that hyperuricemia and the gouty arthritis that causes are thus shown effect repeatedly, tophus deposition, gouty kidney and dysbolismus pathological changes are shown effect for seeing with gouty arthritis repeatedly.Along with people's living standard improves, the change of nutrition and diet structure, the gout sickness rate is and obviously increases trend.
The traditional Chinese medical science thinks that the joint meridians that stagnate flow by the resistance of the turbid damp stasis of blood in gout system, and due to QI and blood was smooth, non-general ailment said due to cold or exposure was done.The heresy of turbid damp, non-be subjected in outside, and in main being born in.General patient with gout is mainly in middle-aged and elderly people, plump people, its internal organs degradation, if having a liking for the food greasy and surfeit flavour, infringement function of a specified duration is the most outstanding to damage the pure and impure metabolic function of spleen kidney especially.Dysfunction of the spleen in transportation, ascending the clear and descending the turbid is had no right, the weary gasification of kidney, separating clear and excreting turbid mistake department, water paddy is reforming not, gives birth in the turbid poison, is detained in the blood, with the capable distribution of blood, a series of pathological changes takes place.Diseases such as gouty arthritis are the marks of disease, purine metabolism obstacle (the pure and impure metabolism of spleen kidney) is not normal is only disease this, the turbid poison of uric acid is the middle pathological product of pathological changes, and produces disease such as gouty arthritis thus.
The inventor thinks that the cause of disease of gout mainly is that institute causes by " give birth in damp and hot, the turbid poison, diseases caused by retention of fluid is stagnated ", so the rule of treatment is worked as based on heat clearing and damp drying, detoxifcation, diuretic, easing joint movement.
Summary of the invention
The invention provides a kind of new Chinese medicine composition, said composition has the effect of heat clearing and damp drying, detoxifcation, diuretic, easing joint movement, is used for the treatment of gout.
Another object of the present invention provides the preparation method of above-mentioned Chinese medicine composition.
The present invention is achieved by the following technical solutions:
The present invention is made by the following weight proportion raw material: Rhizoma Smilacis Glabrae 15-60 part, Radix Cyathulae 4.5-9 part, Cortex Phellodendri 3-12 part, Radix Et Rhizoma Rhei 3-30 part, Rhizoma Alismatis 6-9 part, Herba Plantaginis 9-30 part.
Preferred weight portion proportioning is: 30 parts of Rhizoma Smilacis Glabraes, 6 parts of Radix Cyathulaes, 9 parts of Cortex Phellodendris, 6 parts of Radix Et Rhizoma Rhei, 6 parts of Rhizoma Alismatis, 20 parts of Herba Plantaginiss.
The preparation method of Chinese medicine composition of the present invention is as follows:
Above medical material adds 8 times of amount 70% ethanol extractions, extract 2 times, each 1-1.5 hour, being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract, add appropriate amount of auxiliary materials, be prepared into pharmaceutically acceptable oral formulations, for example capsule, tablet, pill, drop pill etc.
The preparation method of the preferred pill of Chinese medicine composition of the present invention is as follows:
Extract is ground into fine powder, adds proper honey, evenly mixed, the pill agent.
The preparation method of Chinese medicine composition preferred capsule of the present invention agent is as follows:
Extract is ground into fine powder, adds lactose, mixing is used 95% alcohol granulation, and drying incapsulates, and promptly gets capsule.
The preparation method of the preferred tablet of Chinese medicine composition of the present invention is as follows:
Extract is ground into fine powder, adds lactose, mixing is granulated, drying, and the adding magnesium stearate is an amount of, mixing, tabletting, coating promptly gets tablet.
The compatibility mechanism of pharmaceutical composition of the present invention is as follows:
The traditional Chinese medical science thinks that the joint meridians that stagnate flow by the resistance of the turbid damp stasis of blood in gout system, and due to QI and blood was smooth, non-general ailment said due to cold or exposure was done.The heresy of turbid damp, non-be subjected in outside, and in main being born in.General patient with gout is mainly in middle-aged and elderly people, plump people, its internal organs degradation, if having a liking for the food greasy and surfeit flavour, infringement function of a specified duration is the most outstanding to damage the pure and impure metabolic function of spleen kidney especially.Dysfunction of the spleen in transportation, ascending the clear and descending the turbid is had no right, the weary gasification of kidney, separating clear and excreting turbid mistake department, water paddy is reforming not, gives birth in the turbid poison, is detained in the blood, with the capable distribution of blood, a series of pathological changes takes place.Diseases such as gouty arthritis are the marks of disease, purine metabolism obstacle (the pure and impure metabolism of spleen kidney) is not normal is only disease this, the turbid poison of uric acid is the middle pathological product of pathological changes, and produces disease such as gouty arthritis thus.
The inventor thinks that the cause of disease of gout mainly is that institute causes by " give birth in damp and hot, the turbid poison, diseases caused by retention of fluid is stagnated ", so the rule of treatment is worked as based on heat clearing and damp drying, detoxifcation, diuretic, easing joint movement.
In the drug composition, the mechanism of action of each medicine is as follows in the present invention:
Rhizoma Smilacis Glabrae: sweet, light, flat.Return liver, stomach warp.Dehumidifying, detoxifcation, easing joint movement.Be used for damp and hot stranguria with turbid discharge, leukorrhagia, carbuncle, the limbs contracture due to the scrofula, scabies, syphilis and mercurialism, bones and muscles pain.
Radix Cyathulae: sweet, little hardship, flat.Return liver, kidney channel.Eliminating blood stasis and inducing menstruation, easing joint movement, inducing diuresis for treating stranguria syndrome.Be used for amenorrhea and mass in the abdomen, retention of placenta, arthralgia, flaccidity of the lower limbs clonic spasm of the muscle, hematuria stranguria with blood, injury from falling down.
Cortex Phellodendri: hardship, cold.Return kidney, urinary bladder channel.Heat clearing and damp drying, pathogenic fire purging are removed and are steamed, and skin ulcer is treated in detoxifcation.Be used for damp-heat dysentery, jaundice, leukorrhagia, pyretic stranguria, beriberi, flaccidity is warded off, hectic fever due to YIN-deficiency consumptive fever, night sweat, seminal emission, sore swollen toxin, eczema pruritus.The stir-baked CORTEX PHELLODENDRI with salt solution nourishing YIN to lower pathogenic fire.Be used for hyperactivity of fire caused by deficiency of YIN, the night sweat hectic fever due to YIN-deficiency.
Radix Et Rhizoma Rhei: hardship, cold.Return spleen, stomach, large intestine, liver, pericardium channel.Purging heat and dredging bowels, removing pathogenic heat from blood and toxic substance from the body, eliminating blood stasis and inducing menstruation.Be used for the excess-heat constipation, stagnant stomachache, dysentery is not well, jaundice due to damp-heat, heat in blood is told nosebleed, conjunctival congestion, pharyngeal swelling, abdominalgia with intestinal abscess, carbuncle furuncle, blood stasis amenorrhea, traumatic injury, external treatment burn due to hot liquid or fire; Upper gastrointestinal hemorrhage.Radix et Rhizoma Rhei (stir-fried with wine) is apt to clear part of the body cavity above the diaphragm housing the heart and lungs noxious heat in the blood system.Be used for the conjunctival congestion pharyngeal swelling, gingivitis.Radix Et Rhizoma Rhei rushes down exerts oneself to delay eliminating fire and detoxication.Be used for pathogenic fire,toxin and furuncles.The hemostasis of charred Radix Et Rhizoma Rhei cooling blood and removing stasis.Be used for heat in blood stasis of blood hemorrhage is arranged.
Rhizoma Alismatis: sweet, cold.Return kidney, urinary bladder channel.Diuresis, clearing away damp-heat.Be used for dysuria, edema distension, the oliguria of having loose bowels, dizziness due to fluid-retention, the puckery pain of pyretic stranguria; Hyperlipidemia.
Herba Plantaginis: sweet, cold.Return liver, kidney, lung, small intestine meridian.Clearing away heat and promoting diuresis is eliminated the phlegm, removing heat from blood, detoxifcation.Be used for the edema oliguria, the puckery pain of pyretic stranguria, heat-damp in summer dysentery, phlegm-heat cough, hematemesis and epistaxis, carbuncle sore tumefacting virus.
In the present invention in the drug composition with Rhizoma Smilacis Glabrae as monarch drug, bring into play the effect of its dehumidifying, detoxifcation, easing joint movement, Cortex Phellodendri, Radix Et Rhizoma Rhei are as ministerial drug, play the effect of heat clearing and damp drying, removing pathogenic heat from blood and toxic substance from the body, Rhizoma Alismatis, Herba Plantaginis make for assistant altogether, get the effect of its clearing away heat and promoting diuresis, and Radix Cyathulae is strengthened the effect of easing joint movement, six medicines are harmonious, and play the effect of heat clearing and damp drying, detoxifcation, diuretic, easing joint movement altogether.
Below, foregoing of the present invention is described in further detail by the specific embodiment:
Concrete embodiment
Embodiment 1:
Rhizoma Smilacis Glabrae 30kg, Radix Cyathulae 6kg, Cortex Phellodendri 9kg, Radix Et Rhizoma Rhei 6kg, Rhizoma Alismatis 6kg, Herba Plantaginis 20kg
Above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, and each 1 hour, being concentrated into relative density was the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract;
Extract is ground into fine powder, adds proper honey, evenly mixed, the pill agent.
Embodiment 2:
Rhizoma Smilacis Glabrae 30kg, Radix Cyathulae 6kg, Cortex Phellodendri 6kg, Radix Et Rhizoma Rhei 9kg, Rhizoma Alismatis 6kg, Herba Plantaginis 20kg
Above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, and each 1 hour, being concentrated into relative density was the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract;
Extract is ground into fine powder, adds the 30kg lactose, mixing is used 95% alcohol granulation, and drying incapsulates, and promptly gets capsule.
Embodiment 3:
Rhizoma Smilacis Glabrae 30kg, Radix Cyathulae 9kg, Cortex Phellodendri 9kg, Radix Et Rhizoma Rhei 6kg, Rhizoma Alismatis 6kg, Herba Plantaginis 20kg
Above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, and each 1 hour, being concentrated into relative density was the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract;
Extract is ground into fine powder, adds the 30kg lactose, mixing is granulated, drying, and the adding magnesium stearate is an amount of, mixing, tabletting, coating promptly gets tablet.
Embodiment 4:
Rhizoma Smilacis Glabrae 20kg, Radix Cyathulae 6kg, Cortex Phellodendri 9kg, Radix Et Rhizoma Rhei 6kg, Rhizoma Alismatis 6kg, Herba Plantaginis 20kg
Above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, and each 1 hour, being concentrated into relative density was the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract;
Extract is ground into fine powder, adds proper honey, evenly mixed, the pill agent.
Embodiment 5:
Rhizoma Smilacis Glabrae 30kg, Radix Cyathulae 4.5kg, Cortex Phellodendri 6kg, Radix Et Rhizoma Rhei 9kg, Rhizoma Alismatis 6kg, Herba Plantaginis 20kg
Above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, and each 1 hour, being concentrated into relative density was the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract;
Extract is ground into fine powder, adds the 30kg lactose, mixing is used 95% alcohol granulation, and drying incapsulates, and promptly gets capsule.
Embodiment 6:
Rhizoma Smilacis Glabrae 30kg, Radix Cyathulae 9kg, Cortex Phellodendri 12kg, Radix Et Rhizoma Rhei 6kg, Rhizoma Alismatis 6kg, Herba Plantaginis 20kg
Above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, and each 1 hour, being concentrated into relative density was the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract;
Extract is ground into fine powder, adds the 30kg lactose, mixing is granulated, drying, and the adding magnesium stearate is an amount of, mixing, tabletting, coating promptly gets tablet.
Embodiment 7:
Rhizoma Smilacis Glabrae 30kg, Radix Cyathulae 6kg, Cortex Phellodendri 9kg, Radix Et Rhizoma Rhei 12kg, Rhizoma Alismatis 6kg, Herba Plantaginis 20kg
Above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, and each 1 hour, being concentrated into relative density was the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract;
Extract is ground into fine powder, adds proper honey, evenly mixed, the pill agent.
Embodiment 8:
Rhizoma Smilacis Glabrae 30kg, Radix Cyathulae 6kg, Cortex Phellodendri 6kg, Radix Et Rhizoma Rhei 9kg, Rhizoma Alismatis 9kg, Herba Plantaginis 20kg
Above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, and each 1 hour, being concentrated into relative density was the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract;
Extract is ground into fine powder, adds the 30kg lactose, mixing is used 95% alcohol granulation, and drying incapsulates, and promptly gets capsule.
Embodiment 9:
Rhizoma Smilacis Glabrae 30kg, Radix Cyathulae 9kg, Cortex Phellodendri 9kg, Radix Et Rhizoma Rhei 6kg, Rhizoma Alismatis 6kg, Herba Plantaginis 30kg
Above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, and each 1 hour, being concentrated into relative density was the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract;
Extract is ground into fine powder, adds the 30kg lactose, mixing is granulated, drying, and the adding magnesium stearate is an amount of, mixing, tabletting, coating promptly gets tablet.
Further set forth the beneficial effect of pharmaceutical composition of the present invention by following experiment:
The laboratory observation of traditional Chinese medicine composition for treating rat gout model of the present invention
1 materials and methods
1.1 laboratory animal and grouping
30 of Wistar cleaning level male rats, body weight 200-250g is divided into normal group, gout model group and Chinese herb prevention group at random, 10 every group.
1.2 the preparation of urate crystal
With reference to the Seemiller method, uric acid (Uric acid) is dissolved in the NaOH solution of 1mol/L, adjust pH with HCl, through stirring, filtration, cold drying, screening, sterilize, be prepared into aseptic urate crystal.
1.3 gout Preparation of model
The scorching animal model of experimental uric acid salt ankle joint is made with reference to Coderre TJ and the improvement of Chen Shi method and is carried out.With sterile working's method, with No. 4 injection needles,, inject the articulatio tibiotarsalis intracavity of gout model group and Chinese herb prevention group rat right hind leg internal malleolus with 5% urate solution, 50 μ l, each animal is only injected 1 time.
1.4 medicine
Treatment group rat is raised with Chinese medicine composition medicinal liquid of the present invention, with 10 times of amounts of per kilogram of body weight of people, 4h left and right sides gastric infusion after modeling in the preparation of gout model.Irritate stomach every day 1 time, continuously 3d.Normal group and gout model group rat are irritated isopyknic normal saline.
1.5 observation index
1.5.1 general signs
Observe the outward appearance of rat right hind leg internal malleolus articulatio tibiotarsalis, the active situation of limbs etc.
1.5.2 the K+ concentration of right side ankle joint and surrounding tissue thereof
After modeling the 4th day, the sacrificed by decapitation animal is got hot-tempered joint, right side and surrounding tissue thereof, weighs, homogenate, centrifuging and taking supernatant, with the K+ concentration of the U.S. SYNCHRON EL-ISE of Beckman company analysis-e/or determining tissue.
1.5.3 the tissue pathologies change of right side ankle joint and surrounding tissue thereof
Get right side ankle joint and surrounding tissue thereof, make light microscopic and detect.With conventional method with specimen fix, decalcification, paraffin embedding, section, HE dyeing.
2 results
2.1 general signs
Gout model group and treatment rat, after being injected urate solution about the 2nd day (about 24h), the articulatio tibiotarsalis of internal malleolus has occurred all that ankle swelling in various degree, slow, the sufficient pawl of walking are curled, limbs are reluctant to put forth effort to bear a heavy burden, and individual animal hind leg occurs and excessively bows in the wrongly, even walks lamely.After the modeling day, treatment was organized right ankle swelling and is disappeared obviously, various signs on the whole, the gout model group overweights the treatment group.
2.2 the K+ concentration of right side ankle joint and surrounding tissue thereof
The K+ concentration of gout model group ankle joint and surrounding tissue thereof is apparently higher than normal group (p＜0.05), and no tangible difference (table 1) between treatment group and the normal group.
The K+ concentration of table 1 ankle joint and surrounding tissue thereof (x ± S)
Compare * p＜0.05 with normal group
2.3 the tissue pathologies change of ankle joint and surrounding tissue thereof
Normal group: ankle joint and structures surrounding thereof are normally clear, do not have any tissue pathologies change.
The gout model group: finding during topography has the urate crystal calmness in the ankle joint intracavity.The visible down significantly arthritis pathology of light microscopic changes, there is tangible foreign body granuloma to form around the tibia shank, show as the more foreign body multinucleated giant cell of appearance in the foreign body granuloma tissue, newborn little vascularization and more fibroblast, local cartilaginous tissue is destroyed.
Treatment group: the urate crystal calmness is arranged in the ankle joint intracavity.Visible arthritis pathology changes under the light microscopic, and the foreign body multinucleated giant cell is less sees, has newborn little vascularization and the local cartilaginous tissue of less fibroblast that destruction is also arranged.But on the population structure, significantly better than the gout model group, what have has almost recovered normal.
3 these experimental results of conclusion have pointed out utilization Chinese medicine composition of the present invention to be used for the treatment of the rat acute gout model that caused by the local injection urate, can obtain comparatively satisfied effect.General signs takes a turn for the better, the PATHOMORPHOLOGICAL OBSERVATION OF PULLORUM that the swelling of ankle joint has the K+ concentration of significantly disappear joint and surrounding tissue thereof obviously to reduce tissue also shows, the pathological change of treatment group arthritis compares with the gout model group, improves significantly on population structure.Chinese medicine composition of the present invention can effectively be treated gout.
Claims (6)
1, a kind of Chinese medicine composition that is used for the treatment of gout is characterized in that, it is to be made by following bulk drugs: Rhizoma Smilacis Glabrae 15-60 part, Radix Cyathulae 4.5-9 part, Cortex Phellodendri 3-12 part, Radix Et Rhizoma Rhei 3-30 part, Rhizoma Alismatis 6-9 part, Herba Plantaginis 9-30 part.
According to the Chinese medicine composition of claim 1, it is characterized in that 2, it is to be made by following bulk drugs: 30 parts of Rhizoma Smilacis Glabraes, 6 parts of Radix Cyathulaes, 9 parts of Cortex Phellodendris, 6 parts of Radix Et Rhizoma Rhei, 6 parts of Rhizoma Alismatis, 20 parts of Herba Plantaginiss.
3, the preparation method of claim 1 or 2 described Chinese medicine compositions, it is characterized in that this method is: above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, each 1-1.5 hour, being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract, add appropriate amount of auxiliary materials, be prepared into pharmaceutically acceptable oral formulations, for example capsule, tablet, pill, drop pill etc.
4, the preparation method of Chinese medicine composition according to claim 3 is characterized in that, the preparation method of pill is: extract is ground into fine powder, adds proper honey, and evenly mixed, the pill agent.
5, the preparation method of Chinese medicine composition according to claim 3 is characterized in that, the preparation method of capsule is: extract is ground into fine powder, adds lactose, mixing is used 95% alcohol granulation, and drying incapsulates, and promptly gets capsule.
6, the preparation method of Chinese medicine composition according to claim 3 is characterized in that, the preparation method of tablet is: extract is ground into fine powder, adds lactose, mixing is granulated, drying, and the adding magnesium stearate is an amount of, mixing, tabletting, coating promptly gets tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101132159A CN101590168B (en) | 2008-05-27 | 2008-05-27 | Traditional Chinese medicine combination for treating gout and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101132159A CN101590168B (en) | 2008-05-27 | 2008-05-27 | Traditional Chinese medicine combination for treating gout and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101590168A true CN101590168A (en) | 2009-12-02 |
| CN101590168B CN101590168B (en) | 2012-07-18 |
Family
ID=41405168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101132159A Active CN101590168B (en) | 2008-05-27 | 2008-05-27 | Traditional Chinese medicine combination for treating gout and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101590168B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105582438A (en) * | 2015-12-31 | 2016-05-18 | 孙伟 | Traditional Chinese medicine composition for treating gout and preparation method of traditional Chinese medicine composition |
| CN105687351A (en) * | 2014-11-27 | 2016-06-22 | 韦健宁 | Chinese medicinal composition for treatment of gout |
| CN107095950A (en) * | 2017-05-05 | 2017-08-29 | 胡永兰 | It is a kind of to treat medicine pill of gout and preparation method thereof |
| CN109865030A (en) * | 2017-12-04 | 2019-06-11 | 海南诺倍尔生态医学科学研究院有限公司 | A kind of Chinese medicine preparation that treating gout and preparation method |
| CN111150799A (en) * | 2020-03-13 | 2020-05-15 | 张书侨 | Composition for preventing and treating hyperuricemia and gout as well as preparation method and application thereof |
| CN111494508A (en) * | 2020-03-25 | 2020-08-07 | 广西冠硕科技有限公司 | Preparation method of traditional Chinese medicine gout plaster and product thereof |
| CN114601902A (en) * | 2020-12-08 | 2022-06-10 | 安劲海 | Traditional Chinese medicine formula for treating hyperuricemia and gout |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100348248C (en) * | 2005-01-11 | 2007-11-14 | 贵阳新天药业股份有限公司 | Chinese medicinal composition for treating gout and its preparing process |
| CN1326553C (en) * | 2005-11-23 | 2007-07-18 | 安徽省药物研究所 | Medicine for treating gout and preparing method |
-
2008
- 2008-05-27 CN CN2008101132159A patent/CN101590168B/en active Active
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105687351A (en) * | 2014-11-27 | 2016-06-22 | 韦健宁 | Chinese medicinal composition for treatment of gout |
| CN105582438A (en) * | 2015-12-31 | 2016-05-18 | 孙伟 | Traditional Chinese medicine composition for treating gout and preparation method of traditional Chinese medicine composition |
| CN107095950A (en) * | 2017-05-05 | 2017-08-29 | 胡永兰 | It is a kind of to treat medicine pill of gout and preparation method thereof |
| CN109865030A (en) * | 2017-12-04 | 2019-06-11 | 海南诺倍尔生态医学科学研究院有限公司 | A kind of Chinese medicine preparation that treating gout and preparation method |
| CN111150799A (en) * | 2020-03-13 | 2020-05-15 | 张书侨 | Composition for preventing and treating hyperuricemia and gout as well as preparation method and application thereof |
| CN111494508A (en) * | 2020-03-25 | 2020-08-07 | 广西冠硕科技有限公司 | Preparation method of traditional Chinese medicine gout plaster and product thereof |
| CN111494508B (en) * | 2020-03-25 | 2022-03-01 | 广西冠硕科技有限公司 | Preparation method of traditional Chinese medicine gout plaster and product thereof |
| CN114601902A (en) * | 2020-12-08 | 2022-06-10 | 安劲海 | Traditional Chinese medicine formula for treating hyperuricemia and gout |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101590168B (en) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101590168B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN101590184B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN101062372A (en) | Chinese herbal medicine preparation for dissolving hepatobiliary system calculi | |
| CN105412406A (en) | Traditional Chinese medicine composition for reducing blood viscosity and preparing method thereof | |
| CN101032593A (en) | Acne-treating Chinese medicine preparation | |
| CN106266463B (en) | Traditional Chinese medicine composition for treating hyperuricemia and application thereof | |
| CN101590169B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN101590167B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN102671178B (en) | Preparation method of Chinese medicinal composition for treating nephrotic syndrome and uremia and application thereof | |
| CN103285119A (en) | Chinese medicine composition for treating autoimmune liver disease, and preparation method thereof | |
| CN101590166B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN100443112C (en) | Medicine for treating gout and gout arthritis | |
| CN102038778B (en) | Chinese medicinal composition with effects of relaxing meridians, activating collaterals, expelling wind and removing dampness and preparation method thereof | |
| CN102091285B (en) | Medicinal preparation for clearing heat and restoring consciousness, preparation method thereof and application thereof | |
| CN106166262A (en) | A kind of Chinese medicine composition treating chronic renal failure | |
| CN101028421B (en) | Chinese medicine for treating chronic kidney failure | |
| CN104721313A (en) | Nursing medicine for treating acute waist injury | |
| CN1083269C (en) | Chinese herbal medicine for treating hysteromyoma and breast fibrosarcoma and its prepn. method | |
| CN107510765A (en) | A kind of Chinese medicine composition for treating phlegm-blood stasis numbness network type rheumatic Bi syndrome and preparation method thereof | |
| CN1180826C (en) | Medicament for promoting exhaustion from anus and its preparation method | |
| CN101757369A (en) | Medicine composition for treating acute goutry arthritis and preparation process thereof | |
| CN106880673A (en) | It is a kind of to treat Chinese medicine composition of coronary heart disease and preparation method thereof | |
| CN106668787A (en) | Traditional Chinese medicine honeyed pill for treating hepatonecrosis and liver cancer and preparation method of traditional Chinese medicine honeyed pill | |
| CN102641472B (en) | Chinese herbal preparation for curing osteoporosis | |
| CN105617276A (en) | Medicine composition for treating rectal prolapse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee after: BEIJING INCREASE PHARMACEUTICAL INSTITUTE Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee after: BEIJING INCREASE PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP03 | Change of name, title or address |
Address after: Double camp 102299 West Road Beijing city Changping District Science Park No. 79, No. 24 building 6 layer cloud Valley Park Patentee after: Beijing Increasepharm Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL INSTITUTE Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180301 Address after: 102206 Beijing City, Changping District small town life Zhongguancun Life Science Park Road No. 8 School District No. 15 Building 5 layer Patentee after: Beijing YingKeRui Pharmaceutical Safety and Effectiveness Research Co.,Ltd. Address before: Double camp 102299 West Road Beijing city Changping District Science Park No. 79, No. 24 building 6 layer cloud Valley Park Patentee before: Beijing Increasepharm Co.,Ltd. |
|
| TR01 | Transfer of patent right |